Why the study?
Amyloid-beta (1-40) is associated with MACE in patients with established cardiovascular disease, but its clinical significance and association with subclinical cardiac and coronary artery disease in the general population without overt CVD were unknown.
Cross-Sectional (n=3,266)
No
Answers are grounded in this paper and cite their sources.
In a general population without clinically overt cardiovascular disease, circulating plasma Aβ40 levels are independently associated with markers of subclinical cardiac stress and injury (NT-proBNP, hs-cTnT) and lower cardiorespiratory fitness (VO2 max).
Amyloid-beta (1-40) (Aβ40), a peptide with proinflammatory and proatherosclerotic properties, is associated with arterial aging [(1)][1] and with major adverse cardiovascular events in patients with stable coronary heart disease, heart failure, or acute coronary syndrome [(1–3)][1]. However, the
No takes yet. Share an insight, caveat, or question.
Stamatelopoulos et al. (2018) conducted a cross-sectional in General population without clinically overt cardiovascular disease (n=3,266). Circulating plasma Amyloid-beta (1-40) (Aβ40) levels was evaluated on Subclinical cardiovascular disease (cMRI markers, CAC, NT-proBNP, hs-cTnT) and cardiorespiratory fitness (VO2 max).
Synapse has enriched 10 related papers. Consider them for comparative context: